secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001437749-25-006012
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics authorizes $5M share repurchase program through Feb 2026
------------------------------------------------------------------------------

- Board authorized repurchase of up to $5M of common stock; program runs through Feb 28, 2026.
- CEO Thomas Jensen cites confidence in stenoparib’s clinical potential and long-term vision.
- Company says sufficient cash position maintains runway into 2026, unaffected by buyback.
- Repurchases discretionary; may be made via open market or other methods under Rule 10b-18.
- Allarity is a Phase 2 clinical-stage biotech developing dual PARP/Wnt inhibitor stenoparib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/0001437749-25-006012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/allr20250303_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer